Moberg Pharma AB (STU:MB8)
€ 2.82 0.042 (1.51%) Market Cap: 133.65 Mil Enterprise Value: 105.38 Mil PE Ratio: 0 PB Ratio: 1.62 GF Score: 18/100

Twelve Months 2020 Moberg Pharma AB (publ) Earnings Call Transcript

Aug 11, 2020 / 01:00PM GMT
Operator

Hello, and welcome to the Moberg Pharma conference call. (Operator Instructions) Just to remind you, this call is being recorded. Today, I'm pleased to present Anna Ljung. Please begin your meeting.

Anna Ljung;publ;CEO
Moberg Pharma AB

()-

Thank you. Hello, everyone. My name is Anna Ljung, and I'm the CEO of Moberg Pharma. I also have our VP of Finance, Mark Beveridge with me here today. And I'm happy to present our interim report covering this last quarter, April to June. And you can find the report on our web page. And there, you can also find a PowerPoint presentation that I will use in this telephone meeting.

So I will start on Page 4 in that presentation, with a brief summary. So we're a Swedish pharmaceutical company that base our products on drug delivery of known substances, which reduces time to market and development risk compared to traditional drug development. We have a clinical pipeline consisting of 2 late-stage drug candidates, MOB-015 and BUPI, both of which have demonstrated strong clinical results,

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot